Literature DB >> 9882914

[Does neoadjuvant radiochemotherapy augment the resectability of pancreatic cancers?].

J Bousquet1, K Slim, D Pezet, M Alexandre, P Verrelle, H Cure, J Chipponi.   

Abstract

PURPOSE OF THE STUDY: Pre-operative radiochemotherapy is the most recent therapeutic option in the pre-operative downstaging of pancreatic cancer and in decreasing the rate of positive resection margins. The purpose of the study was to evaluate tolerance and efficacy of pre-operative radiochemotherapy in unresectable pancreatic cancers.
MATERIAL AND METHODS: This study included seven cases of pancreatic cancer considered unresectable. The patients received preoperatively 50 grays within a 5-week period associated with 5 FU and Platin during the 1st and 5th weeks.
RESULTS: After radiochemotherapy, tomodensitometric evaluation showed a minor response in two cases. A pancreatico-duodenectomy could be performed in these two patients without any increase of pre- or post-operative morbidity or mortality.
CONCLUSIONS: The results of the study suggest that preoperative radiochemotherapy may increase pancreatic cancer resectability. This hypothesis should be confirmed by a prospective randomised trial.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9882914     DOI: 10.1016/s0001-4001(99)80072-5

Source DB:  PubMed          Journal:  Chirurgie        ISSN: 0001-4001


  2 in total

1.  Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas.

Authors:  V K Mehta; G Fisher; J A Ford; J C Poen; M A Vierra; H Oberhelman; J Niederhuber; J A Bastidas
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

2.  Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?

Authors:  Hong Jin Kim; Karen Czischke; Murray F Brennan; Kevin C Conlon
Journal:  J Gastrointest Surg       Date:  2002 Sep-Oct       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.